Results 271 to 279 of about 21,216 (279)

Mutations Associated with Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor In Vitro

Antimicrobial Agents and Chemotherapy, 2008
Luba Tchertanov, Jean-François Mouscadet   +1 more
exaly  

Long‐Term Efficacy and Safety of Raltegravir Combined with Optimized Background Therapy in Treatment‐Experienced Patients with Drug‐Resistant HIV Infection: Week 96 Results of the BENCHMRK 1 and 2 Phase III Trials

Clinical Infectious Diseases, 2010
Joseph J Eron, Jose M Gatell, Mauro Schechter   +2 more
exaly  

Single‐ and Multiple‐Dose Pharmacokinetics of Once‐Daily Formulations of Raltegravir

Clinical pharmacology in drug development, 2018
R. Krishna, M. Rizk, P. Larson, V. Schulz, F. Kesisoglou, R. Pop   +5 more
semanticscholar   +1 more source

Raltegravir with Optimized Background Therapy for Resistant HIV-1 Infection

New England Journal of Medicine, 2008
Mauro Schechter, Mona R Loutfy, Jeffrey L Lennox   +2 more
exaly  

Durable Efficacy and Safety of Raltegravir Versus Efavirenz When Combined With Tenofovir/Emtricitabine in Treatment-Naive HIV-1–Infected Patients

Journal of Acquired Immune Deficiency Syndromes (1999), 2013
Jeffrey L Lennox
exaly  

Raltegravir versus lopinavir/ritonavir for treatment of HIV-infected late-presenting pregnant women

HIV Clinical Trials, 2018
C. Brites, I. Nóbrega, Estela Luz, A. Travassos, Cynthia Lorenzo, E. Netto   +5 more
semanticscholar   +1 more source

Raltegravir

Reactions Weekly
openaire   +1 more source

Dolutegravir (S/GSK1349572) Exhibits Significantly Slower Dissociation than Raltegravir and Elvitegravir from Wild-Type and Integrase Inhibitor-Resistant HIV-1 Integrase-DNA Complexes

Antimicrobial Agents and Chemotherapy, 2011
exaly  

High Rate of Virologic Suppression with Raltegravir plus Etravirine and Darunavir/Ritonavir among Treatment‐Experienced Patients Infected with Multidrug‐Resistant HIV: Results of the ANRS 139 TRIO Trial

Clinical Infectious Diseases, 2009
exaly